Sutro Biopharma STRO Noncash Lease Expenses
Noncash Lease Expenses at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept stro:NoncashLeaseExpenses.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's noncash lease expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's noncash lease expenses?
- Sutro Biopharma (STRO) reported noncash lease expenses of $1.2M in Q1 2026.
- How has Sutro Biopharma's noncash lease expenses changed year-over-year?
- Sutro Biopharma's noncash lease expenses decreased by 14.4% year-over-year, from $1.4M to $1.2M.
- What is the long-term trend for Sutro Biopharma's noncash lease expenses?
- Over 4 years (2021 to 2025), Sutro Biopharma's noncash lease expenses has grown at a 4.5% compound annual growth rate (CAGR), from $4.93M to $5.88M.
- What does noncash lease expenses mean?
- This represents the portion of lease expenses recognized in the income statement that does not involve an immediate cash outflow, typically related to the amortization of right-of-use assets. It is added back to net income in the cash flow statement to reflect the company's actual cash-based operating performance. Monitoring this helps investors distinguish between accounting-based lease costs and actual cash obligations.